Evidence map›Paper›PMID 29712821›Full record

ArticleHaematologica2018

Osteoprotective medication in the era of novel agents: a European perspective on values, risks and future solutions.

Monika Engelhardt, Georg W Herget, Giulia Graziani, Gabriele Ihorst, Heike Reinhardt, Stefanie Ajayi, Stefan Knop, Ralph Wasch

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Monika EngelhardtDepartment of Medicine I, Hematology, Oncology & Stem Cell Transplantation, Medical Center, University of Freiburg, Germany monika.engelhardt@uniklinik-freiburg.de.
Georg W HergetDepartment of Orthopedics and Trauma Surgery, Medical Center, University of Freiburg, Germany.
Giulia GrazianiDepartment of Medicine I, Hematology, Oncology & Stem Cell Transplantation, Medical Center, University of Freiburg, Germany.
Gabriele IhorstClinical Trials Unit, Medical Center, University of Freiburg, Germany.
Heike ReinhardtDepartment of Medicine I, Hematology, Oncology & Stem Cell Transplantation, Medical Center, University of Freiburg, Germany.
Stefanie AjayiDepartment of Medicine I, Hematology, Oncology & Stem Cell Transplantation, Medical Center, University of Freiburg, Germany.
Stefan KnopHematology, Oncology, Gastroenterology, University of Würzburg, Germany.
Ralph WaschDepartment of Medicine I, Hematology, Oncology & Stem Cell Transplantation, Medical Center, University of Freiburg, Germany.
University of Freiburg · DEUniversity of Würzburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Bone Density Conservation AgentsBone DiseasesEuropeHumansMultiple MyelomaPrognosisProtective AgentsBone Density Conservation AgentsProtective Agents

Identifiers

PMID29712821
PMCPMC5927973
OpenAlexW2799596981

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.